Monte Rosa Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
GLUE Nasdaq 2830 www.monterosatx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Monte Rosa Therapeutics, Inc.

Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise - Apr 21st, 2026 11:53 am
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors - Apr 20th, 2026 5:00 am
Monte Rosa J J Supply Deal Refocuses MRT 2359 Prostate Cancer Story - Mar 21st, 2026 5:07 am
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday Ahead of US Federal Reserve Meeting - Mar 17th, 2026 6:56 am
Monte Rosa Therapeutics touts molecular glue pipeline, tees up GFORCE updates and Phase II plans - Mar 17th, 2026 6:40 am
Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates - Mar 17th, 2026 6:25 am
Monte Rosa Therapeutics: Q4 Earnings Snapshot - Mar 17th, 2026 5:33 am
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates - Mar 17th, 2026 5:00 am
Agenus (AGEN) Q4 Earnings and Revenues Surpass Estimates - Mar 16th, 2026 6:35 pm
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer - Mar 16th, 2026 5:00 am
Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Mar 12th, 2026 8:00 am
Assessing Monte Rosa Therapeutics (GLUE) Valuation After MRT-2359 Data Update And New Public Offering - Mar 7th, 2026 10:09 pm
How Monte Rosa’s MRT-2359 Prostate Cancer Data and Funding Plans Could Shape GLUE’s Risk‑Reward Profile - Mar 7th, 2026 7:06 pm
Kura Oncology (KURA) Reports Q4 Loss, Misses Revenue Estimates - Mar 5th, 2026 5:40 am
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU) - Feb 24th, 2026 5:00 am
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - Feb 23rd, 2026 5:00 am
NeoGenomics (NEO) Q4 Earnings and Revenues Surpass Estimates - Feb 17th, 2026 6:15 am
Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) institutional investors lost 12% last week but have benefitted from longer-term gains - Feb 6th, 2026 8:21 am
Assessing Monte Rosa Therapeutics (GLUE) Valuation After Strong MRT-8102 Phase 1 Data And Share Price Momentum - Jan 10th, 2026 8:12 am
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering - Jan 8th, 2026 8:49 pm